In FDC-S diagnosis, FDCSP and SRGN showed both a good sensitivity, higher than CD23 and Claudin 4, and an extremely good specificity, evaluated on 214 controls including carcinomas, soft tissue tumors, melanomas, thymomas and interdigitating dendritic cell sarcomas. This evidence concerns the gene CLDN4 and soft tissue neoplasm.